Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — H1 FY2024 Earnings Presentation
21 slides from Zim Laboratories's earnings presentation, Nov 1, 2023
Slide 1: Exchange filing cover letter: Q2 & H1FY24 Earnings Presentation
Ref No.: ZLL/CS/BSE/NSE Date: 01.11.2023 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) D
Slide 2: Innovation and Differentiation for Patient-Centric Solutions
INNOVATION AND DIFFERENTIATION FOR PATIENT-CENTRIC SOLUTIONS Q2 & H1FY24 – EARNINGS PRESENTATION
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: ZIM Labs at a Glance
ZIM LABS AT A GLANCE o Novel Drug Delivery System Using Proprietary Manufacturing Processes o ZIM develops and supplies combination generic products utilizing innovative drug delivery Rs. 1532 Mn solutions using various in-house technology platforms H1FY24 Revenue o Sustainable R&D Spend o The R&D s
Slide 5: Highlights: Q2FY24
HIGHLIGHTS : Q2FY24 NIP and OTF contribution increasing Improved Run Rates in Total Operating Income For Q2FY24, there was a 53.6% QoQ growth in NIP Our Total Operating Income grew by 27.3%, reaching revenue, reaching Rs. 72 Mn Rs. 858 Mn in Q2FY24, up from Rs. 674 Mn in OTF revenue in Q2FY24 was Rs
Slide 6: Growth Trajectory
GROWTH TRAJECTORY Total Operating Income (Rs. Mn) EBITDA (Rs. Mn) & EBITDA Margin 1,050 1,054 15.6% 15.3% 15.3% 1,010 14.3% 14.1% 13.8% 994 13.1% 927 12.5% 867 858 775 10.1% 164 161 8.8% 155 674 642 131 137 111 114 107 65 59 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q1FY2
Slide 7: Business Mix
BUSINESS MIX Total Pharma Revenue (Rs. Mn) & as % of Total Operating Income Total Nutra Revenue (Rs. Mn) & as % of Total Operating Income 95% 93% 89% 86% 86% 33% 80% 77% 77% 75% 67% 25% 23% 23% 20% 940 310 807 805 14% 14% 764 761 740 245 249 664 617 230 11% 613 540 7% 134 5% 111 114 118 60 29 Q1FY22
Slide 8: Momentum Seen in NIP and OTF
MOMENTUM SEEN IN NIP AND OTF NIP Revenue (Rs. Mn) & as (%) of Total Operating Income OTF Revenue (Rs. Mn) & as (%) of Total Operating Income 8% 24 26 29 26 17 26 27 9 23 37 7% 4% 4% 4% 3% 3% 3% 72 3% 2% 3% 2% 3% 2% 45 2% 47 1% 2% 25 27 1% 23 0% 22 17 21 21 2 13 11 8 20 18 17 17 1% Q1FY22 Q2FY22 Q3FY
Slide 9: Geographical Mix Improving: Risk Is Diversified Across Regions
GEOGRAPHICAL MIX IMPROVING: RISK IS DIVERSIFIED ACROSS REGIONS Business Mix (Rs. Mn) Region wise Business Mix (%) Q1FY24 Q2FY24 46, 7% 55, 6% 89, 13% 43% 125, 15% 32% 32% 33% 678, 79% 29% 539, 80% 23% 20% 21% Exports India Deemed Exports Exports India Deemed Exports 16% 15% Q2FY23 10% 10% 73, 7% 7%
Slide 10: Committed to Core Strategy
COMMITED TO CORE STRATEGY Current Business: Q2FY24 Outlook Pharmaceuticals Nutraceuticals Pharmaceuticals; New Innovative Products Nutraceuticals Generic Products Generic Products Branded Generics / OTF 10 3 3 PFI FF/OTF PFI/FF FF NIP Dossiers NIP Fillings New Products filed planned for the (Various
Slide 11: R&D at Core
R&D AT CORE ZIM’s Technology Platforms R&D Expense Mix % of Total R&D Spend & Total R&D Spend as % of Total Operating Income ( ) • Focus on using Differentiated Drug Delivery techniques • Non – infringing development and manufacturing processes 9% 33% 28% using various technology platforms – 17% 9.4
Slide 12: Income Statement
INCOME STATEMENT Change % Change % Particulars (Rs. Mn) H1FY24 H1FY23 (YoY) Q2FY24 Q1FY24 (QoQ) Total Operating Income 1, 532 1, 921 (20.2%) 858 674 27.3% Other Income 25 33 (24.2%) 14 11 27.3% Total Income 1, 557 1, 954 (20.3%) 872 685 27.3% EBITDA 166 268 (38.1%) 107 59 81.4% EBITDA % 10.8% 14.0%
Slide 13: Balance Sheet
BALANCE SHEET Particulars (Rs. Mn) H1FY24 FY23 FY22 FY21 Gross Block :Tangible & Intangible Assets including WIP 2, 596 2, 257 1, 920 1, 762 Net Block- Tangible Assets including WIP 1, 453 1, 216 1, 069 1, 052 Net Block Intangible Assets including WIP 162 141 105 120 Other Non- Current Assets 146 15
Slide 14: Balance Sheet Indicators
BALANCE SHEET INDICATORS Gross Block Addition (Rs. Mn) Gross Block (Rs. Mn) 2, 596 73 158 337 339 2, 257 38 1, 920 76 1, 762 301 261 17 141 16 57 FY21 FY22 FY23 H1FY24 Intangible Assets Tangible Assets FY21 FY22 FY23 H1FY24 Net Worth (Rs. Mn) Borrowings (Rs. Mn) & Gearing (%) 2, 260 811 2, 003 1, 75
Slide 15: H1 & Q2FY24 – Financial Performance
H1 & Q2FY24 – FINANCIAL PERFORMANCE TotalTotal Operating Income Operating Income(Rs (Rs.Mn) Mn) EBITDA (Rs. Mn) & EBITDA % PAT (Rs. Mn) & PAT % 14% 10.8% 5.5% 2.8% 1, 921 268 1, 532 106 166 43 H1FY23 H1FY24 H1FY23 H2FY24 H1FY23 H1FY24 858 8.8% 12.5% 0.3% 4.8% 107 674 41 59 2 Q1FY24 Q2FY24 Q1FY24 Q2F
Slide 16: Historical Income Statement
HISTORICAL INCOME STATEMENT Particulars (Rs. Mn) FY23 FY22 FY21 FY20 Total Operating Income 3, 985 3, 334 3, 073 2, 777 Other Income 64 44 23 45 Total Income 4, 049 3, 378 3, 096 2, 822 EBITDA 584 454 421 271 EBITDA % 14.7% 13.6% 13.7% 9.8% Profit Before Tax (PBT) 354 210 154 1 Profit after Tax (PAT
Slide 17: Corporate
CORPORATE 16
Slide 18: Shareholding
SHAREHOLDING Ownership % (On Sep 23) Traded Volume (In K) BSE+NSE 22,128 18,399 6% 4% 15,690 33% 18% 6,112 1,662 169 78 49 84 69 86 28 204 609 307 222 232 343 Nov Apr '22 Sept Jan'23 May June Aug June Sept Aug Oct Mar Feb July July Dec May April Volume(Shares) 39% Promoter o During Q1FY24, the equit
Slide 19: Share Price Movement
SHARE PRICE MOVEMENT ZIM (BSE) vs BSE S&P Healthcare Index ZIM vs Nifty Healthcare Index 28, 194 9, 608 9, 622 26, 789 128 123 8, 550 106 111 113 8, 317 128 123 8, 009 23, 875 83 82 87 90 111 113 79 79 7923, 681 106 70 69 71 73 61 90 91 51 22, 364 22, 182 87 21, 699 79 79 79 Nov-22 Dec-22 Jan-23 Feb
Slide 20: Q2FY24 Earnings Call Details
Q2FY24 EARNINGS CALL DETAILS Date 9th November, 2023 Time 12 Noon IST Dial – In Details Universal Access Numbers +91-22-62801557/ +91-22-71158383 Diamond Pass Click Here 19
Slide 21: Thank You
Visit ZIM Laboratories Limited: https://www.zimlab.in/ For further information, please get in touch with: ZIM’s Investor Relations Mr. Zain Daud ir@zimlab.in M: +91 9022434631 GoIndia Advisors – IR Firm Ms. Sheetal Khanduja Ms. Deepika Sharma Ms. Priya Sen sheetal@goindiaadvisors.com deepika@goindia